PMID- 30425519
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade 
      glioma patients: a systematic review and meta-analysis.
PG  - 7277-7293
LID - 10.2147/OTT.S177768 [doi]
AB  - BACKGROUND: Dendritic cell (DC)-based vaccine is a promising therapy for 
      high-grade gliomas (HGGs); however, its actual effectiveness still remains 
      controversial. This meta-analysis aims to extensively evaluate the efficacy and 
      safety of DC vaccine for HGG patients. METHODS: We systematically searched 
      PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant 
      parallel randomized controlled trials (RCTs) and properly controlled 
      non-randomized studies (NRS) published in English. Two investigators reviewed all 
      the texts and extracted information regarding overall survival (OS), 
      progression-free survival (PFS), and adverse events (AEs) from eligible studies. 
      Sensitivity analyses and subgroup analyses were also conducted. RESULTS: Of 353 
      suitable studies, 13 studies (three RCTs and ten NRS) involving 944 patients were 
      finally included. Compared to the control therapy group (CT group), the DC group 
      showed better OS and PFS without serious AEs. Subgroup analysis showed that 
      trials designed as NRS obtained better results in the DC group in this study; 
      however, no specific subgroup regarding dosages, cycles or injection routes was 
      found to be superior in the DC group compared to the CT group. CONCLUSION: DC 
      vaccine can significantly improve OS and PFS, with acceptable toxicity, of HGG 
      patients. Nevertheless, further studies are needed to verify this conclusion.
FAU - Li, Changling
AU  - Li C
AD  - Department of Experimental Medicine, Northern Hospital, Shenyang 110016, China, 
      hyingy@sina.com.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of General Practice, The Second Hospital of Dalian Medical University, 
      Dalian 116023, China, byqf_2011@163.com.
FAU - Zhou, Bo
AU  - Zhou B
AD  - Department of Clinical Epidemiology and Evidence-based Medicine, The First 
      Affiliated Hospital, China Medical University, Shenyang 110001, China.
FAU - Zhou, Yubin
AU  - Zhou Y
AD  - Department of Oncology, The People's Hospital of China Medical University, 
      Shenyang 110015, China.
FAU - Yu, Huiying
AU  - Yu H
AD  - Department of Experimental Medicine, Northern Hospital, Shenyang 110016, China, 
      hyingy@sina.com.
FAU - Sun, Yun
AU  - Sun Y
AD  - Department of General Practice, The Second Hospital of Dalian Medical University, 
      Dalian 116023, China, byqf_2011@163.com.
LA  - eng
PT  - Journal Article
DEP - 20181024
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6204866
OTO - NOTNLM
OT  - dendritic cell
OT  - glioblastoma multiforme
OT  - high-grade gliomas
OT  - overall survival
OT  - progression-free survival
OT  - vaccine
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:01
PMCR- 2018/10/24
CRDT- 2018/11/15 06:00
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:01 [medline]
PHST- 2018/10/24 00:00 [pmc-release]
AID - ott-11-7277 [pii]
AID - 10.2147/OTT.S177768 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Oct 24;11:7277-7293. doi: 10.2147/OTT.S177768. 
      eCollection 2018.